E3330 | APE1 inhibitor/ferroptosis inducer
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $90.00 | ||
| 25 mg | $325.00 |
E3330 (136164-66-4) is a hepatoprotective benzoquinone that inhibits TNF-α release via decreasing NFkB activation.1,2 It also is an inhibitor of AP endonuclease 1 (APE1) redox function.3 E3330 acts synergistically with cisplatin to increase cytotoxicity and impair cell migration and invasion in non-small cell lung cancer.4 Inhibition of APE1 with E3330 induces ferroptosis via impairment of AKT phosphorylation ultimately leading to Nrf2 degradation.5 It sensitizes osteosarcoma cells to ionizing radiation via ferroptosis induction.6
References/CItations:
- Nagakawa et al. (1992), Protective effects of (2E)-3-[5-(2,3-dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonyl-2-propenoic acid; J. Pharmacol. Exp. Ther. 262 145
- Goto et al. (1996), Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B; Mol. Pharmacol. 49 860
- Zou and Maitra et al. (2008), Small-molecule inhibitor of AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration; Mol. Cancer Ther. 7 2012
- Manguinhas et al. (2020), Impact of the APE1 Redox Function Inhibitor E3330 in Non-small Cell Lung Cancer Cells Exposed to Cisplatin: Increased Cytotoxicity and Impairment of Cell Migration and Invasion; Antioxidants (Basel) 9 550
- Du et al. (2024), APE1 inhibition enhances ferroptotic cell death and contributes to hepatocellular carcinoma therapy; Cell Death Differ. 31 431
- Xiao et al. (2024), Inhibitors of APE1 redox and ATM synergistically sensitize osteosarcoma cells to ionizing radiation by inducing ferroptosis; Int. Immunopharmacol. 139 112672
C21H30O6
>98% HPLC
NMR: (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
E3330 (136164-66-4) is a hepatoprotective benzoquinone that inhibits TNF-α release via decreasing NFkB activation.1,2 It also is an inhibitor of AP endonuclease 1 (APE1) redox function.3 E3330 acts synergistically with cisplatin to increase cytotoxicity and impair cell migration and invasion in non-small cell lung cancer.4 Inhibition of APE1 with E3330 induces ferroptosis via impairment of AKT phosphorylation ultimately leading to Nrf2 degradation.5 It sensitizes osteosarcoma cells to ionizing radiation via ferroptosis induction.6
References/CItations:
- Nagakawa et al. (1992), Protective effects of (2E)-3-[5-(2,3-dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonyl-2-propenoic acid; J. Pharmacol. Exp. Ther. 262 145
- Goto et al. (1996), Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B; Mol. Pharmacol. 49 860
- Zou and Maitra et al. (2008), Small-molecule inhibitor of AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration; Mol. Cancer Ther. 7 2012
- Manguinhas et al. (2020), Impact of the APE1 Redox Function Inhibitor E3330 in Non-small Cell Lung Cancer Cells Exposed to Cisplatin: Increased Cytotoxicity and Impairment of Cell Migration and Invasion; Antioxidants (Basel) 9 550
- Du et al. (2024), APE1 inhibition enhances ferroptotic cell death and contributes to hepatocellular carcinoma therapy; Cell Death Differ. 31 431
- Xiao et al. (2024), Inhibitors of APE1 redox and ATM synergistically sensitize osteosarcoma cells to ionizing radiation by inducing ferroptosis; Int. Immunopharmacol. 139 112672
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
